Factor VIIa (Recombinant) For Acquired Hemophilia
Coagulation factor VIIa (recombinant) (NovoSeven, Novo Nordisk) is the first recombinant therapy to be approved for the treatment of bleeding episodes and for the prevention of bleeding in patients with acquired hemophilia who are undergoing invasive surgical procedures. First introduced in 1999, NovoSeven is currently indicated for the treatment of bleeding episodes in hemophilia A [...]
Read User's Comments